Wednesday, February 10, 2010, 12:28PM AEST - The Australian Stockmarket closes in 3 hours and 37 minutes.
To create a watchlist or portfolio of shares, Register

Unigene Laboratories Inc. (UGNE.OB)

5:29AM AEST: 0.59 USD  Down 0.01 (1.67%)  
 MORE ON UGNE.OB 
Quotes
HereSummary
Charts
Technical Analysis
News & Info
Company
Analyst Coverage
Ownership
Financials
 UNIGENE LABS INC (OTC BB:UGNE.OB) Delayed quote dataEdit
Last Trade:0.59 USD
Trade Time: 5:29AM AEST
Change:Down 0.01 (1.67%)
Prev Close:0.60
Open:0.57
Bid:0.59 x 2500
Ask:0.62 x 2500
1y Target Est:2.60
Day's Range:0.57 - 0.59
52wk Range:0.37 - 1.96
Volume:12,360
Avg Vol (3m):125,506
Market Cap:53.93M
P/E (ttm):N/A
EPS (ttm):-0.17
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
 Add UGNE.OB to Portfolio   Download Data

 HEADLINES 
Unigene Files Shelf Registration Statement
Business Wire (Thu, Dec 24)
Unigene Announces Promising Preclinical Results in Its Obesity Peptide Program
Business Wire (Fri, Dec 18)
Biotech's Latest Failed Trials, Missed Targets
at Seeking Alpha (Mon, Dec 14)
UNIGENE LABORATORIES INC Files SEC form 8-K, Costs Associated with Exit or Disposal Activities, Financial Statements
EDGAR Online (Sat, Dec 12)
Independent Advisory Committee Recommends Continuation of Phase III Oral Calcitonin Studies for Osteoporosis and Osteoarthritis
Business Wire (Fri, Dec 11)
Unigene Announces Significant Cost Savings and Corporate Restructuring
Business Wire (Wed, Dec 9)
UNIGENE LABORATORIES INC Financials
EDGAR Online Financials (Sat, Nov 14)
UNIGENE LABORATORIES INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
EDGAR Online (Tue, Nov 10)
UNIGENE LABORATORIES INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity
EDGAR Online (Tue, Oct 20)
UNIGENE LABORATORIES INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
EDGAR Online (Tue, Aug 11)
UNIGENE LABORATORIES INC Files SEC form 10-Q, Quarterly Report
EDGAR Online (Tue, Aug 11)
More Headlines for UGNE.OB...

 ANALYST 
EPS Est (next year) (Dec-08) :N/A
EPS Est (in 2 years) (Dec-09) :N/A
Avg Rec (current)*:3.0
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
Unigene Laboratories, Inc., a biopharmaceutical company, engages in the research, production, and delivery of peptides for medical use primarily in the United States.

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
Latest News7 Indices